November 5, 2026 earnings date gives Curis stock a USD 1.00 million estimate

Published on 10/15/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Curis lost USD 8.60 million in the second quarter of 2026. Curis stock costs EUR 0.50 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.

Earnings date and cash position

MarketBeat estimated Curis would report third-quarter results on November 5, 2026, with USD 1.00 million revenue.
Curis held USD 5.1 million in cash on June 30, 2026.
Curis stock costs EUR 0.50 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.
Curis had a USD 1.1 million market capitalization on October 15, 2026.

CRIS, US2312694084, Illustration mit AI erstellt.

An estimated November 5, 2026 reporting date and USD 1.00 million revenue forecast give Curis stock a clear calendar marker. MarketBeat listed the expected third-quarter release before the market opens. Curis stock was trading at EUR 0.50 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.

Second-quarter loss reached USD 8.6 million

Curis reported a net loss attributable to common shareholders of USD 8.6 million for the second quarter ended June 30, 2026. Diluted earnings per share were negative USD 4.02 for that period. The first-quarter loss had been USD 24.2 million, making the second-quarter result USD 15.6 million less negative on a quarter-to-quarter basis.

The stock sits near its yearly low

On Nasdaq, Curis was last at USD 0.55 on October 15, 2026 at 2:55 p.m. ET, down 8.34 percent from the previous close of USD 0.60. The finance quote showed a 52-week range of USD 0.55 to USD 33.60, placing the latest Nasdaq price at the lower boundary of that range. The same quote showed 129,896 shares traded against an average volume of 203,604 shares.

Cash and November date

Cash and cash equivalents stood at USD 5.1 million on June 30, 2026, down from USD 15.0 million at March 31, 2026. Operating cash flow was negative USD 9.6 million in the second quarter, compared with negative USD 9.0 million in the first quarter. The November 5 reporting date remains the next scheduled company event identified by MarketBeat.

Comparison with peers

Curis (Nasdaq, USD): minus 8.34 percent, P/E minus 0.04, market capitalization USD 1.1 million.
Kura Oncology (Nasdaq, USD): plus 1.40 percent, P/E minus 2.89, market capitalization USD 866.9 million.
Acrivon Therapeutics (Nasdaq, USD): plus 2.33 percent, P/E minus 0.94, market capitalization USD 75.4 million.

Nasdaq quote and euro price

The Nasdaq quotation and the Lang & Schwarz indication present different currency views of the same session. Curis is listed on Nasdaq under the ticker CRIS, according to Global Trade Review. The next report will put the USD 1.00 million revenue estimate against the second-quarter loss and the company cash position.

Curis stock was trading at EUR 0.50 at Lang & Schwarz on October 15, 2026 at 8:49 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Curis stock.